Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Metseras portfolio includes: injectable GLP-1 receptor agonist MET-097i (phase 2), amylin analog candidate MET-233i (phase I), two oral GLP-1 RA candidates expected to begin clinical trials imminently, and additional preclinical nutrient-stimulated hormone therapeutics
On a different angle, when subjected to DEN-induced hepatocarcinogenesis, overexpression of PGC-1 renders mice more prone to hepatocarcinoma development possibly by enhancing the expression of genes involved in fatty acids and triglycerides synthesis as well as by limiting ROS accumulation via increased antioxidant response 12
Both Ozempic and Zepbound can cost more than $1,000 per month
GLP-1 RA use and survival among older adults with cancer and type 2 diabetes
US$ 26.46
US$ 25.68
US$ 29.38
